Company: ARVN
Filing Date: 2025-05-01
Form Type: 8-K
Source: 0001655759-25-000081
Chunk: 3

Company: ARVINAS, INC.
Filing Date: 2025-05-01
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit No.      Description                                                   
         99.1      Press Release issued by the Registrant on May 1, 2025.        
 ─────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (formatted as Inline XBRL).  

Cautionary Note Regarding Forward-Looking Statements

Statements in this Current Report on Form 8-K about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the extent, timing and financial aspects of the Company’s cost savings plan and associated workforce reduction. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to successfully implement its workforce reduction; the risk that the costs and charges associated with the workforce reduction may be greater than anticipated; the risk that the Company's workforce reduction may affect the Company's ability to retain skilled and motivated personnel and may be distracting to employees and management; the impact of the workforce reduction on the Company’s business and reputation; the Company’s ability to: conduct its ongoing clinical trials of its

product candidates, including vepdegestrant, ARV-393 and ARV-102, and any planned future trials of ARV-806, to enroll patients in ongoing and planned trials, to obtain and maintain necessary approvals from the FDA and other regulatory authorities, to continue to advance its product candidates in preclinical studies and clinical trials, to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates, and to advance the development of its product candidates under the timelines it anticipates in planned and